An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

Running, not enrolling · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Trigeminal Neuralgia

In brief

Trigeminal neuralgia (TN), also called "tic douloureux", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice. This study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN.

Key facts

Study ID
NCT05217628
Run by
Noema Pharma AG
People needed
166
Starts
2022-01-11
Expected to finish
2027-04-24
Last updated by the study team
2026-01-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.